Report shows Big Pharma's patent cliff in graphic detail

The Economist's analysis of Big Pharma's patent cliff woes is worth looking at if only for the accompanying graph and its plunging sales lines for Pfizer's ($PFE) Lipitor, Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix, Novartis' ($NVS) Diovan and Merck's ($MRK) Singulair. Report